Loading company…
Nuvectis Pharma develops precision medicines for cancer.
Founded in 2020 and based in New Jersey, Nuvectis Pharma is developing precision cancer medicines. Its pipeline includes NXP800, an oral small molecule HSF-1 pathway inhibitor, and NXP900, an oral small molecule SRC/YES1 kinase inhibitor. In May 2021, the company raised USD 15.3 million in Series A funding from Sixth Element Capital and other investors. It trades on NASDAQ as NVCT, and Ron Bentsur was CEO as of 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in